Serum Creatinine, a Biomarker for Muscle Mass in Amyotrophic Lateral Sclerosis (ALS), Predicts Loss of Ambulation Measured by ALS Functional Rating Scale-Revised Walking Item Score (ALSFRS-Rw) (P4.085)

CONCLUSIONS:Decrease in serum creatinine significantly predicted change in ambulation measured by ALSFRS-Rw longitudinally.Further analysis is required to determine whether leg function alone and leg muscle mass are the major determinants of serum creatinine in ALS patients over the course of the disease.Study Supported by:Carolinas ALS Research Fund/Pinstripes Fund/Carolinas Garden of Hope/Carolinas Healthcare FoundationDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Brooks has received research support from Biogen Idec, Avanir Pharmaceuticals, Cytokinetics, Neuraltus Pharmaceuticals, GlaxoSmithKline, Inc., and the National Institute of Neurological Disorders and Stroke. Dr. Fischer has nothing to disclose. Dr. Sanjak has nothing to disclose. Dr. Holsten has nothing to disclose. Dr. Kandinov has nothing to disclose. Dr. Bockenek has nothing to disclose. Dr. Bravver has received research support from Biogen Idec, Avanier, Cytokinetics Pharmaceuticals, Neuraltus Pharmaceuticals, GlaxoSmithKline Inc., the National Institute of Neurological Disorders and Stroke, and the Clinical Research Consortium. Dr. Desai has received personal compensation for activities with Purdue Pharma and UCB Pharma as a speaker. Dr. Story has nothing to disclose. Dr. Pacicco has nothing to disclose. Dr. Lindblom has nothing t...
Source: Neurology - Category: Neurology Authors: Tags: ALS: Trials and Biomarkers Source Type: research